MiNK Therapeutics CEO updates Form 4 tax entry

MiNK Therapeutics, Inc. disclosed an amended insider trading report for its chief executive officer.

Rhea-AI Filing Summary

MiNK Therapeutics, Inc. disclosed an amended insider trading report for its chief executive officer. The amendment updates a prior Form 4 to include 10,024 shares of common stock that were withheld on January 2, 2026 to cover withholding taxes related to stock issued to the executive. These shares were not originally shown in Table I of the earlier filing. After this tax withholding transaction at a reported price of $11.12 per share, the executive beneficially owns 57,942 shares of MiNK Therapeutics common stock in direct ownership. The amendment is described as correcting an error in the original Form 4 filed on January 6, 2026.

Insider Trade Summary

Exercise Price or Tax Liability: 10,024 shares

Exercise Price or Tax Liability 1 txn

Insider Buell Jennifer

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	10,024	$11.12	$111K

Holdings After Transaction: Common Stock — 57,942 shares (Direct)

Footnotes (1)

1. F1. These shares were withheld for payment of the withholding taxes in relation to the stock issued to the reporting person on January 2, 2026, as previously reported on the Form 4 filed on January 6, 2026 (the "Original Form 4"). The Original Form 4 did not include the shares withheld for payment of withholding taxes in Table I. This amendment is being filed to correct this error.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MiNK Therapeutics (INKT) report in this amended Form 4?

The company reported that its chief executive officer had 10,024 shares of common stock withheld on January 2, 2026 to pay withholding taxes related to stock issued on that date.

Why did MiNK Therapeutics (INKT) file an amended Form 4?

The amendment was filed because the original Form 4 dated January 6, 2026 did not include in Table I the 10,024 shares that were withheld for payment of withholding taxes, and this filing corrects that error.

How many MiNK Therapeutics (INKT) shares does the reporting person own after this transaction?

Following the reported tax withholding transaction, the reporting person beneficially owns 57,942 shares of MiNK Therapeutics common stock in direct ownership.

What was the price used for the withheld MiNK Therapeutics (INKT) shares?

The 10,024 shares withheld for taxes were reported at a price of $11.12 per share of MiNK Therapeutics common stock.

Does this MiNK Therapeutics (INKT) Form 4/A involve a sale of shares on the open market?

The filing describes shares being withheld for payment of withholding taxes in connection with stock issued to the reporting person, rather than a discretionary open-market sale.

Who signed the amended MiNK Therapeutics (INKT) Form 4?

The amended Form 4 was signed "By: /s/ Austin Charette, Attorney-in-Fact", indicating it was executed under a power of attorney for the reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/14/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Buell Jennifer

(Last) (First) (Middle)

149 FIFTH AVENUE, SUITE 500

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MiNK Therapeutics, Inc. [ INKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)
01/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/02/2026		F		10,024(1)	D	$11.12	57,942	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were withheld for payment of the withholding taxes in relation to the stock issued to the reporting person on January 2, 2026, as previously reported on the Form 4 filed on January 6, 2026 (the "Original Form 4"). The Original Form 4 did not include the shares withheld for payment of withholding taxes in Table I. This amendment is being filed to correct this error.

	By: /s/ Austin Charette, Attorney-in-Fact	01/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.